{"id":389004,"date":"2024-12-23T00:00:00","date_gmt":"2024-12-23T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0016-2024-biopharma-acute-myeloid-leukemia-disease-landscape-forecast-g7-2024\/"},"modified":"2026-03-31T10:27:34","modified_gmt":"2026-03-31T10:27:34","slug":"dlsfon0016-2024-biopharma-acute-myeloid-leukemia-disease-landscape-forecast-g7-2024","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0016-2024-biopharma-acute-myeloid-leukemia-disease-landscape-forecast-g7-2024\/","title":{"rendered":"Acute Myeloid Leukemia | Disease Landscape &#038; Forecast | G7 | 2024"},"content":{"rendered":"<p>Acute myeloid leukemia (AML) is associated with poor outcomes and low five-year overall survival rates. Although chemotherapy has been the mainstay AML treatment for a long time, the recent approval of new drugs, such as Vanflyta (a second-generation FLT-3 inhibitor) and Rezlidhia (an IDH1 inhibitor), indicates a trend toward targeted therapies. Moreover, both early- and late-phase pipelines for AML include various drug classes such as kinase inhibitors, radio-immunotherapeutics, menin inhibitors, therapeutic vaccines, antibody-drug conjugates, and CAR T-cell therapies. With the expected approval of several new treatments and the expansion of existing ones into additional patient populations, we expect substantial growth of the AML drug therapy market.<\/p>\n<p><strong>Questions answered:<\/strong><\/p>\n<ul>\n<li>How large are the clinically and commercially relevant drug-treatable AML populations, and how will drug-treatable rates change (if at all) over the 2023-2033 forecast period?<\/li>\n<li>What is the current treatment landscape for AML? What are the key takeaways from expert interviews?<\/li>\n<li>What are the most promising therapies in the pipeline, and how will they influence the AML therapy market?<\/li>\n<li>What are the primary factors driving and limiting the AML market, and how will this market evolve over the forecast period?<\/li>\n<\/ul>\n<p><strong>Geographies:<\/strong> United States, EU5, Japan<\/p>\n<p><strong>Primary research:<\/strong> 19 country-specific interviews with thought-leading hematologist-oncologists. Supported by survey data collected for this and other Clarivate research.<\/p>\n<p><strong>Epidemiology:<\/strong> Diagnosed incidence cases of AML by country and by clinically and market-relevant drug-treatable populations.<\/p>\n<p><strong>Forecast:<\/strong> 10-year, annualized, drug-level, and regimen-level sales and patient share of key AML therapies through 2033, segmented by brands \/ generics \/ biosimilars and drug-treatable subpopulations.<\/p>\n<p><strong>Drug treatments:<\/strong> Coverage of key current and emerging therapies.<\/p>\n<p><strong>Product description<\/strong><\/p>\n<p>Disease Landscape &#038; Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.<\/p>\n<p><strong>Key features<\/strong><\/p>\n<p>Disease Landscape &#038; Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.<\/p>\n<p>Disease Landscape &#038; Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.<\/p>\n","protected":false},"template":"","class_list":["post-389004","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-acute-myeloid-leukemia","biopharma-date-985"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389004","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389004\/revisions"}],"predecessor-version":[{"id":575851,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389004\/revisions\/575851"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=389004"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}